ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Abatacept"

  • Abstract Number: 2915 • 2019 ACR/ARP Annual Meeting

    Machine-learning Classification Identifies a Subset of Patients That Improve on Abatacept via Modulation of a CD28-Related Pathway

    Bhaven Mehta 1, Jennifer Franks 1, Yiwei Yuan 2, Yue Wang 1, Veronica Berrocal 3, Tammara Wood 1, Cathie Spino 4, David Fox 5, Dinesh Khanna 6 and Michael Whitfield7, 1Geisel School of Medicine at Dartmouth, Hanover, NH, 2Geisel School of Medicine at Dartmouth, Hanover, 3Department of Biostatistics, School of Publich Health, University of Michigan, Ann Arbor, MI, 4University of Michigan, Ann Arbor, MI, 5University of Michigan, Ann Arbor, 6Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, 7Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hannover, NH

    Background/Purpose: We analyzed a phase 2 study designed to assess the efficacy of abatacept in patients with diffuse Systemic Sclerosis (SSc). In this work, we…
  • Abstract Number: 1394 • 2019 ACR/ARP Annual Meeting

    Association Between Baseline Anti-CCP2 Antibody Concentration and Clinical Response After 6 Months of Treatment with Abatacept or a TNF Inhibitor in Biologic-Experienced Patients with RA: Results from a US National Observational Study

    Leslie Harrold 1, Joshua Bryson2, Thomas Lehman 3, Joe Zhuo 3, Sheng Gao 3, Xue Han 4, Amy Schrader 5, Sabrina Rebello 6 and Joel Kremer 7, 1University of Massachusetts and Corrona, LLC, Waltham, MA, 2Bristol-Myers Squibb, Princeton, 3Bristol-Myers Squibb, Princeton, NJ, 4Bristol-Myers Squibb Company, Princeton, NJ, 5Corrona, LLC, Waltham, 6Corrona, LLC, Waltham, MA, 7Albany Medical College, Albany, NY

    Background/Purpose: In the AMPLE trial, patients (pts) with RA with higher baseline anti-CCP2 antibody concentrations showed a better response to treatment with abatacept (ABA) than…
  • Abstract Number: 1411 • 2019 ACR/ARP Annual Meeting

    Positivity of Anti-Ro/SSA Antibody Confer Poor Response and Persistence with Abatacept Therapy

    Yushiro Endo1, Tomohiro Koga 1, Shin-ya Kawashiri 1, Ayako Nishino 1, Momoko Okamoto 1, Shimpei Morimoto 2, Sosuke Tsuji 1, Ayuko Takatani 1, Toshimasa Shimizu 1, Remi Sumiyoshi 1, Takashi Igawa 1, Naoki Iwamoto 1, Kunihiro Ichinose 1, Mami Tamai 1, Hideki Nakamura 1, Tomoki Origuchi 3, Yukitaka Ueki 4, Tamami Yoshitama 5, Nobutaka Eiraku 6, Naoki Matsuoka 7, Akitomo Okada 8, Keita Fujikawa 9, Hiroaki Hamada 10, Tomomi Tsuru 11, Shuji Nagano 12, Yojiro Arinobu 13, Toshihiko Hidaka 14, Yoshifumi Tada 15 and Atsushi Kawakami 16, 1Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan, 2Nagasaki University Hospital Clinical Research Centre, Nagasaki, Japan, 3Nagasaki University School of health sciences, Division of physical therapy, Nagasaki, Japan, 4Sasebo Chuo Hospital Rheumatic and Collagen Disease Center, Sasebo, Japan, 5Yoshitama Clinic for Rheumatic Diseases, Kirishima, Japan, 6Eiraku Clinic for Rheumatic Diseases, Kagoshima, Japan, 7Nagasaki Medical Hospital of Rheumatology, Nagasaki, Japan, 8Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, 9JCHO Isahaya General Hospital Department of Rheumatology, Isahaya, Japan, 10Miyazaki University Hospital, Miyazaki, Japan, 11PS clinic, Fukuoka, Japan, 12Aso Iizuka Hospital, Iizuka, Japan, 13Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Fukuoka, Japan, Fukuoka, Japan, 14Zenjinkai Shimin-no-Mori Hospital, Miyazaki, Japan, 15Saga University Hospital, Saga, Japan, 16Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki

    Background/Purpose: Rheumatoid arthritis (RA) occasionally overlaps Sjogren’s syndrome (SS), and RA patients with secondary SS have a higher disease activity of RA and worse joint…
  • Abstract Number: 1422 • 2019 ACR/ARP Annual Meeting

    Reduction in CD4 TEMRA Cells and Its Association with DAS28 (CRP) < 2.6 Treatment Response with Abatacept in Patients with Early, ACPA+, DMARD-Naïve RA

    Paul Emery1, Yoshiya Tanaka 2, Vivian Bykerk 3, Clifton Bingham 4, Thomas Huizinga 5, Gustavo Citera 6, Sean Connolly 7, Kuan-Hsiang Gary Huang 7, Yedid Elbez 8, Sumanta Mukherjee 7 and Roy Fleischmann 9, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Hospital for Special Surgery, New York City, NY, 4Johns Hopkins University, Baltimore, MD, 5Leiden University Medical Center, Leiden, Netherlands, 6Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 7Bristol-Myers Squibb, Princeton, NJ, 8Excelya, Boulogne-Billancourt, France, 9Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: T-cell profiles are heterogeneous between individuals and consist of naïve T cells, memory T cells (including effector memory T cells [TEM] and central memory…
  • Abstract Number: 1423 • 2019 ACR/ARP Annual Meeting

    Patient-Reported Outcomes of Abatacept in Combination with MTX in Early, MTX-Naïve, ACPA Positive Patients with RA: 1-Year Results from a Phase IIIb Study

    Paul Emery1, Yoshiya Tanaka 2, Vivian Bykerk 3, Clifton Bingham 4, Thomas Huizinga 5, Gustavo Citera 6, Joe Zhuo 7, Kuan-Hsiang Gary Huang 8, Robert Wong 7, Sean Connolly 8, Yedid Elbez 9 and Roy Fleischmann 10, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Hospital for Special Surgery, New York City, NY, 4Johns Hopkins University, Baltimore, MD, 5Leiden University Medical Center, Leiden, Netherlands, 6Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 7Bristol-Myers Squibb, Princeton, 8Bristol-Myers Squibb, Princeton, NJ, 9Excelya, Boulogne-Billancourt, France, 10Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Early biologic use can improve long-term control of RA, and early use of abatacept (ABA) + MTX has demonstrated sustained improvements in selected patient-reported…
  • Abstract Number: 1424 • 2019 ACR/ARP Annual Meeting

    The Effect of HLA-DRB1 Risk Alleles (Shared Epitope) on Changes in Immune Cell Subsets and Disease Activity Following Treatment with Abatacept versus Adalimumab in Seropositive Biologic-Naïve Patients with Early, Moderate-to-Severe RA: Data from a Head-to-Head Single-Blinded Trial

    Jane Buckner1, Vivian Bykerk 2, V. Michael Holers 3, S. Louis Bridges 4, William Rigby 5, Sheng Gao 6, Marleen Nys 7 and Neelanjana Ray 8, 1Benaroya Research Institute, Seattle, WA, 2Hospital for Special Surgery, New York City, NY, 3University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, 4University of Alabama at Birmingham, Birmingham, 5Dartmouth-Hitchcock Medical Center, Lebanon, 6Bristol-Myers Squibb, Princeton, NJ, 7Bristol-Myers Squibb, Braine L’Alleud, Belgium, 8Bristol-Myers Squibb, Princeton

    Background/Purpose: Mechanistic differences between biologic DMARDs are poorly understood. Exploring these mechanisms includes assessing the role of HLA-DRB1 alleles containing the shared epitope (SE), which…
  • Abstract Number: 1425 • 2019 ACR/ARP Annual Meeting

    Effect of ACPA IgM Serostatus on Efficacy Outcomes Following Treatment with Abatacept or Adalimumab: A Post Hoc Analysis of a Phase III Head-to-Head Trial

    Thomas Huizinga1, René Toes 1, Michael Weinblatt 2, Michael Schiff 3, Roy Fleischmann 4, Yedid Elbez 5, Sean Connolly 6, Michael Maldonado 6 and Sheng Gao 6, 1Leiden University Medical Center, Leiden, Netherlands, 2Brigham and Women's Hospital, Boston, MA, USA, Boston, MA, 3University of Colorado, Denver, CO, 4Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 5Excelya, Boulogne-Billancourt, France, 6Bristol-Myers Squibb, Princeton, NJ

    Background/Purpose: Anti-citrullinated protein antibody (ACPA) is a marker for early, erosive RA.1 In the Abatacept (ABA) versus adaliMumab (ADA) comParison in bioLogic-naïvE RA subjects with…
  • Abstract Number: 1429 • 2019 ACR/ARP Annual Meeting

    Results at 6 Months of Abatacept vs TNF-α Blockers in Patients with Severe, Long-standing, DMARDs Resistant Rheumatoid Arthritis

    Omar Valenzuela 1, Sebastian Ibanez2, Maria Paz Poblete 3, Claudia Mardones 2, Francisco Silva 2, Maria Jose Villar 2 and Katherine Mogollones 1, 1Facultad de Medicina Clinica Alemana -UDD, Santiago, Region Metropolitana, Chile, 2Facultad de Medicina Clinica Alemana - UDD, Santiago, Region Metropolitana, Chile, 3Rheumatology dpt., Facultad de Medicina Clinica Alemana - UDD, Santiago, Region Metropolitana, Chile

    Background/Purpose: Since January 2016, Chilean patients with rheumatoid arthritis (RA), with severe activity despite the use of 3 DMARDs for at least 6 months, have guaranteed access…
  • Abstract Number: 1437 • 2019 ACR/ARP Annual Meeting

    Comparison of the Efficacy and Safety of Abatacept in Rheumatoid Arthritis Patients with and Without Interstitial Lung Disease

    Sho Sasaki1, Akira Ishii 2, Mai Sugiyama 2, Yuto Izumi 2, Yoko Nakagome 2, Kazuki Hirano 3, Takayoshi Kurabayashi 1, Noriko Sasaki 2, Chiho Yamada 2 and Shinji Sato 4, 1Tokai Universitiy School of Medicine, Isehara, Japan, 2Tokai University School of Medicine, Isehara, Japan, 3Tokai University School of Medicine, Isehara, 4Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Yokohama, Japan

    Background/Purpose: Interstitial lung disease (ILD) is one of complication in patients with rheumatoid arthritis (RA) and its presence often has an effect on the management…
  • Abstract Number: 1442 • 2019 ACR/ARP Annual Meeting

    Comparison of Sustained Clinical Remission And/or Low Disease Activity Rate Between Rapidly and Gradually De-escalation of Abatacept in Rheumatoid Arthritis

    MASAOMI YAMASAKI1, 1Shin-Yokohama Arthritis and Rheumatology Clinic, Yokohama, Japan

    Background/Purpose: However biological DMARDs (bDMARDs) and treatment strategies have improved the outcomes of rheumatoid arthritis (RA), it is unknown who can taper or stop bDMARDs…
  • Abstract Number: 2383 • 2018 ACR/ARHP Annual Meeting

    Pharmacovigilance of Biologics for Non-Systemic Juvenile Idiopathic Arthritis By the German Biologics Registry

    Gerd Horneff1, Gerd Ganser2, Ivan Foeldvari3, Frank Weller-Heinemann4, Kirsten Minden5 and Ariane Klein6, 1Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, 2Klinik für Kinder-und Jugendrheumatologie, Nordwestdeutsches Rheumazentrum, Sendenhorst, Germany, 3Hamburg Centre for Pediatric Rheumatology, Hamburg, Germany, 4Prof.-Hess-Kinderklinik, Bremen,, Berlin, Germany, 5Charité–Universitätsmedizin Berlin, Berlin, Germany, 6Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany

    Background/Purpose: Long-term surveillance of biologics is particularly important in pediatric patients (pts) who may require prolonged treatment. Since 2001, the German Biologics JIA Registry (BIKER)…
  • Abstract Number: 2485 • 2018 ACR/ARHP Annual Meeting

    Comparison of Risk for Infection-Related Hospitalization and Associated Costs of Biologic Experienced Rheumatoid Arthritis Patients Treated with Abatacept Versus Other Targeted Disease Modifying Antirheumatic Drugs

    Damemarie Paul1, Laura McDonald1, Alexander Marshall2, Tammy Curtice3, Melissa Lingohr-Smith4, Brandy Menges4 and Jay Lin4, 1Bristol-Myers Squibb, Lawrenceville, NJ, 2HEOR, Bristol-Myers Squibb, Lawrenceville, NJ, 3Bristol-Myers Squibb, Princeton, NJ, 4Novosys Health, Green Brook, NJ

    Background/Purpose: Abatacept is a targeted disease-modifying antirheumatic drug (tDMARD) that has demonstrated a lower risk for infection in comparison with other tDMARDs among rheumatoid arthritis…
  • Abstract Number: 2554 • 2018 ACR/ARHP Annual Meeting

    Abatacept without Methotrexate in Patients with Active Psoriatic Arthritis: A Post Hoc Analysis of a Phase III, Randomized Study

    Vibeke Strand1, Thomas Lehman2, Harris A Ahmad2, Alyssa Johnsen2, Sandhya Balachandar2 and Philip J. Mease3, 1Stanford University, Palo Alto, CA, 2Bristol-Myers Squibb, Princeton, NJ, 3Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

    Background/Purpose: In the randomized, placebo (pbo)-controlled Phase III ASTRAEA study (ClinicalTrials.gov, NCT01860976) patients (pts) with active psoriatic arthritis (PsA) were randomized to abatacept (ABA) or…
  • Abstract Number: 2745 • 2018 ACR/ARHP Annual Meeting

    Clinical and Serological Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab or Abatacept As Steroid-Sparing Agents

    Daniela Rossi1, Irene Cecchi2, Elena Rubini3, Massimo Radin4, Savino Sciascia5 and Dario Roccatello6, 1Department of Medicine and Experimental Oncology, CMID - Center of Research of Immunopathology and Rare Diseases, Turin, Italy, 2Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, 3Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, 4Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, 5Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, 6Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy

    Background/Purpose: At least 2 biological therapies [tocilizumab (TCZ) and abatacept (ABA)] have been proven to be effective in the management of Giant cell arteritis (GCA)…
  • Abstract Number: 115 • 2018 ACR/ARHP Annual Meeting

    CTLA4-Ig/CD86 Interaction on Cultered Human Fibrocytes and Fibroblasts from Systemic Sclerosis Patients

    Maurizio Cutolo1, Paola Montagna2, Stefano Soldano1, Amelia Chiara Trombetta3, Barbara Ruaro4, Paola Contini5, Sabrina Paolino6, Carmen Pizzorni4, Elisa Alessandri4, Massimo Patanè1, Alberto Sulli4, Stefano Scabini7, Emanuela Stratta7 and Renata Brizzolara1, 1Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Polyclinic San Martino Hospital, Genova, Italy, Genoa, Italy, 2Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS Polyclinic San Martino, University of Genoa, Genova, Italy, 3Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS Polyclinic San Martino, University of Genoa, Genoa, Italy, 4Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, 5Division of Clinical Immunology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino, Genova, Italy, Genova, Italy, 6Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genova, Italy, 7Oncologic Surgery, Department of Surgery, IRCCS Polyclinic San Martino, Genova, Italy, Genoa, Italy

    Background/Purpose: CTLA4-Ig interacts with the cell surface costimulatory molecule CD86 and can downregulate the target cell activation [1]. Circulating fibrocytes (CFs) express markers of both…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology